Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Montreal Heart Institute
With
AstraZeneca
The aim of this study is to identify and evaluate cardiotoxicity in patients with diagnosis of breast cancer, lymphoma or leukemia scheduled to receive anthracycline-based chemotherapy (Cohort A: prospective evaluation); and patients undergoing or having received within the last 5 years anthracycline-based chemotherapy (Cohort B: retrospective and prospective evaluations). Part A and B will be conducted in parallel. This study also has the objectif of identifying biomarkers of cardiotoxicity including inflammatory response proteins and clonal hematopoiesis.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Age 18 years or older at time of CT initiation
Signed informed consent
Patients with diagnosis of breast cancer,lymphoma or leukemia (including autografted subjects)
Planned, ongoing or completed (within last 5 years) chemotherapy with anthracycline
Left ventricular ejection fraction (LVEF) ≥50% pre-chemotherapy
The participant is willing to undergo CMR scans and all other required study procedures
You may not be if
Known cardiomyopathy and/or LVEF \<50%
Known heart failure
History of myocardial infarction (MI)
Clinically significant cardiac valvular disease
Clinically significant pericardial effusion
Allografted subjects
Contraindications to CMR testing (Cohort A \& prospective evaluation for Cohort B):
* Pacemakers, other metallic implants or severe claustrophobia
* Weight \> 135 kg
* Patients with a history of previous allergic reaction to gadolinium
* Patients with history of seizure
* Renal insufficiency (eGFR of \< 45ml/min/1.73m2 using the MDRD equation)
* Pregnant or breastfeeding women
Clareo Health | Identification and Evaluation of Patients at Risk of Developing Cardiotoxicity After Receiving Chemotherapy for Breast Cancer, Lymphoma or Leukemia
